Core Insights - Septerna, Inc. reported a quarterly loss of $0.09 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.19, marking an earnings surprise of -147.37% [1] - The company's revenues for the quarter ended September 2025 were $21.5 million, missing the Zacks Consensus Estimate by 71.34%, compared to revenues of $0.18 million a year ago [2] - The stock has underperformed, losing about 19.2% since the beginning of the year, while the S&P 500 gained 14.4% [3] Financial Performance - Over the last four quarters, Septerna has surpassed consensus EPS estimates only once [2] - The current consensus EPS estimate for the upcoming quarter is $0.26 on revenues of $46.5 million, and for the current fiscal year, it is -$1.00 on revenues of $140.34 million [7] Industry Context - Septerna operates within the Medical - Biomedical and Genetics industry, which is currently ranked in the top 36% of over 250 Zacks industries [8] - The industry has shown a strong correlation between near-term stock movements and trends in earnings estimate revisions, indicating that the performance of Septerna may be influenced by broader industry trends [5][8] Future Outlook - The company's earnings outlook will be crucial for assessing future stock performance, particularly in light of management's commentary during the earnings call [4] - The estimate revisions trend for Septerna was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market [6]
Septerna, Inc. (SEPN) Reports Q3 Loss, Misses Revenue Estimates